Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

Wolfgang M Brueckl; Martin Reck; Achim Rittmeyer; Jens Kollmeier; Claas Wesseler; Gunther H Wiest; Petros Christopoulos; Albrecht Stenzinger; Amanda Tufman; Petra Hoffknecht; Bernhard Ulm; Fabian Reich; Joachim H. Ficker; Eckart Laack

doi:10.21037/tlcr-21-197

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

Wolfgang M Brueckl^* (First author), Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H Wiest, Petros Christopoulos, Albrecht Stenzinger, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich (Co-author), Joachim H. Ficker (Co-author), Eckart Laack

^*Corresponding author for this work

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Original Article (Journal) › peer-review

28 Citations (Web of Science)

Original language	English
Pages (from-to)	309-3105
Journal	TRANSLATIONAL LUNG CANCER RESEARCH
Volume	10
Issue number	7
DOIs	https://doi.org/10.21037/tlcr-21-197
Publication status	Published - 2021

Keywords

OPEN-LABEL
NIVOLUMAB
PHASE-3
PEMBROLIZUMAB
ATEZOLIZUMAB
MULTICENTER
PLACEBO

Access to Document

10.21037/tlcr-21-197

Cite this

Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Stenzinger, A., Tufman, A., Hoffknecht, P., Ulm, B., Reich, F., Ficker, J. H., & Laack, E. (2021). Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. TRANSLATIONAL LUNG CANCER RESEARCH, 10(7), 309-3105. https://doi.org/10.21037/tlcr-21-197

@article{a3e2be0bf7d44d8489de17c4eb228ce1,

title = "Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV",

keywords = "OPEN-LABEL, NIVOLUMAB, PHASE-3, PEMBROLIZUMAB, ATEZOLIZUMAB, MULTICENTER, PLACEBO",

author = "Brueckl, {Wolfgang M} and Martin Reck and Achim Rittmeyer and Jens Kollmeier and Claas Wesseler and Wiest, {Gunther H} and Petros Christopoulos and Albrecht Stenzinger and Amanda Tufman and Petra Hoffknecht and Bernhard Ulm and Fabian Reich and Ficker, {Joachim H.} and Eckart Laack",

note = "Br{\"u}ckl; Ficker; Reich: Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany; Paracelsus Medical University Nuremberg, Nuremberg, Germany; ",

year = "2021",

doi = "10.21037/tlcr-21-197",

language = "English",

volume = "10",

pages = "309--3105",

journal = "TRANSLATIONAL LUNG CANCER RESEARCH",

issn = "2218-6751",

publisher = "AME PUBLISHING COMPANY",

number = "7",

}

Brueckl, WM, Reck, M, Rittmeyer, A, Kollmeier, J, Wesseler, C, Wiest, GH, Christopoulos, P, Stenzinger, A, Tufman, A, Hoffknecht, P, Ulm, B, Reich, F , Ficker, JH & Laack, E 2021, 'Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV', TRANSLATIONAL LUNG CANCER RESEARCH, vol. 10, no. 7, pp. 309-3105. https://doi.org/10.21037/tlcr-21-197

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. / Brueckl, Wolfgang M (First author); Reck, Martin; Rittmeyer, Achim et al.
In: TRANSLATIONAL LUNG CANCER RESEARCH, Vol. 10, No. 7, 2021, p. 309-3105.

Research output: Contribution to journal › Original Article (Journal) › peer-review

TY - JOUR

T1 - Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

AU - Brueckl, Wolfgang M

AU - Reck, Martin

AU - Rittmeyer, Achim

AU - Kollmeier, Jens

AU - Wesseler, Claas

AU - Wiest, Gunther H

AU - Christopoulos, Petros

AU - Stenzinger, Albrecht

AU - Tufman, Amanda

AU - Hoffknecht, Petra

AU - Ulm, Bernhard

AU - Reich, Fabian

AU - Ficker, Joachim H.

AU - Laack, Eckart

N1 - Brückl; Ficker; Reich: Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany; Paracelsus Medical University Nuremberg, Nuremberg, Germany;

PY - 2021

Y1 - 2021

KW - OPEN-LABEL

KW - NIVOLUMAB

KW - PHASE-3

KW - PEMBROLIZUMAB

KW - ATEZOLIZUMAB

KW - MULTICENTER

KW - PLACEBO

U2 - 10.21037/tlcr-21-197

DO - 10.21037/tlcr-21-197

M3 - Original Article (Journal)

C2 - 34430350

SN - 2218-6751

VL - 10

SP - 309

EP - 3105

JO - TRANSLATIONAL LUNG CANCER RESEARCH

JF - TRANSLATIONAL LUNG CANCER RESEARCH

IS - 7

ER -

Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH et al. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. TRANSLATIONAL LUNG CANCER RESEARCH. 2021;10(7):309-3105. doi: 10.21037/tlcr-21-197